Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Novo Nordisk will no longer be working with Hims & Hers Health, and direct access to Wegovy (semaglutide) will no longer be available. In a news release, Novo Nordisk said the collaboration ended ...

CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSema suggest the drug is comparable to Eli Lilly’s Zepbound on safety and efficacy, further data indicating that ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a ...

Reuters FILE PHOTO: Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023, after Eli Lilly and Co on Wednesday said it will cut list prices by 70% for its most commonly ...

Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug can reduce the amount of lean mass lost during weight reduction with Eli ...

2. FDA decision upheld: Two federal judges have backed the FDA’s decision to declare shortages of Zepbound, Mounjaro, Ozempic and Wegovy as resolved.